All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the initial results of ADC-based combinations?

Jul 5, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

The Multiple Myeloma Hub was pleased to speak to Rajshekhar Chakraborty, Herbert Irving Comprehensive Cancer Center, New York, US. We asked, What are the initial results of antibody–drug conjugate (ADC)-based combinations?

What are the initial results of ADC-based combinations?

Chakraborty begins by summarizing the results of the DREAMM-2 study, which investigated the use of an ADC, belantamab mafodotin, in relapsed/refractory multiple myeloma. Chakraborty then discusses belantamab mafodotin-based combinations, including that with pomalidomide and dexamethasone, and the benefits of using combinations rather than single agents.